论文部分内容阅读
晚期直肠癌(cUICC II和III)患者的多学科综合治疗,可使肿瘤得到更好的长期局部控制。目前正在进行的临床实验,着重于改善无病生存率(DFS)、癌症相关生存率(CSS)、复发风险个体预测的生物标记物组合及新的识别靶点。本文作者对表皮生长因子受体家族中的成员Her-2进行了研究,其表达模式及在直肠癌中的作用尚不明确。研究共纳入264例直肠癌患者(男性192例,女性72例,平均年龄64岁),且患者均接受了德国直肠癌研究小组Ⅱ/Ⅲ期临床实验方案所建议的标准化多学科治疗。通过免疫组化评分及银原
Multidisciplinary treatment of patients with advanced rectal cancer (cUICC II and III) provides better long-term local control of the tumor. Current clinical trials are focusing on biomarker combinations that improve disease-free survival (DFS), cancer-related survival (CSS), individuals at risk of recurrence, and new identification targets. The authors studied Her-2, a member of the epidermal growth factor receptor family, and its expression pattern and its role in rectal cancer is unclear. A total of 264 patients with rectal cancer (192 males and 72 females, mean age 64 years) were enrolled in this study. All patients underwent standardized multidisciplinary treatment as recommended by the German Rectal Cancer Research Team Phase II / III clinical trial. By immunohistochemical score and silver original